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Abstract
Background: Liver cancer is both common and burdensome in Asia. Effective liver cancer control, however, is
hindered by a complex etiology and a lack of coordination across clinical disciplines. We sought to identify
strategies for inclusion in a comprehensive liver cancer control for Asia and to compare qualitative and quantitative
methods for prioritization.
Methods: Qualitative interviews (N = 20) with international liver cancer experts were used to identify strategies
using Interpretative Phenomenological Analysis and to formulate an initial prioritization through frequency analysis.
Conjoint analysis, a quantitative stated-preference method, was then applied among Asian liver cancer experts (N =
20) who completed 12 choice tasks that divided these strategies into two mutually exclusive and exhaustive
subsets. Respondents’ preferred plan was the primary outcome in a choice model, estimated using ordinary least
squares (OLS) and logistic regression. Priorities were then compared using Spearman’s Rho.
Results: Eleven strategies were identified: Access to treatments; Centers of excellence; Clinical education; Measuring social
burden; Monitoring of at-risk populations; Multidisciplinary management; National guidelines; Public awareness; Research
infrastructure; Risk-assessment and referral;a n dTransplantation infrastructure. Qualitative frequency analysis indicated that
Risk-assessment and referral (85%), National guidelines (80%) and Monitoring of at-risk populations (80%) received the
highest priority, while conjoint analysis pointed to Monitoring of at-risk populations (p < 0.001), Centers of excellence (p =
0.002), and Access to treatments (p = 0.004) as priorities, while Risk-assessment and referral was the lowest priority (p =
0.645). We find moderate concordance between the qualitative and quantitative methods (rho = 0.20), albeit
insignificant (p = 0.554), and a strong concordance between the OLS and logistic regressions (rho = 0.979; p < 0.0001).
Conclusions: Identified strategies can be conceptualized as the ABCs of comprehensive liver cancer control as
they focus on Antecedents, Better care and Connections within a national strategy. Some concordance was found
between the qualitative and quantitative methods (e.g. Monitoring of at-risk populations), but substantial differences
were also identified (e.g. qualitative methods gave highest priority to risk-assessment and referral, but it was the
lowest for the quantitative methods), which may be attributed to differences between the methods and study
populations, and potential framing effects in choice tasks. Continued research will provide more generalizable
estimates of priorities and account for variation across stakeholders and countries.
Background
Hepatocellular carcinoma (HCC), the predominant form
of liver cancer, is the sixth most common cancer and
the third most frequent cause of cancer-related death
worldwide [1,2]. At least two thirds of the people who
die each year from HCC live in the Asia-Pacific region
[3]. The majority of patients with HCCs are diagnosed
in the advanced stages of presentation due to the rela-
tive paucity of symptoms in the early stages [4]. Because
of the multifocal and advanced stage of disease at time
of diagnosis, potentially curative treatment for HCC is
not feasible in 80% of patients [5].
Chronic liver disease is closely associated with HCC.
In areas where hepatitis B virus (HBV) is endemic, the
incidence of HCC is high. It has been estimated that
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Asia [6]. However, the etiology of HCC in Japan is dif-
ferent as hepatitis C virus (HCV) is more prevalent than
HBV. Ninety percent of the HCC in Japan is HCV
related [5]. As stated in a recent report by the United
States Institute of Medicine, both HBV and HCV can be
prevented and controlled, which would reduce the inci-
dence of HCC and liver disease [7].
The relative burden and complexity of liver cancer,
especially in Asia, lends itself to a comprehensive cancer
control plan. However, there is a paucity of data or
experience to design such a policy response. While com-
prehensive cancer control plans regularly target lung,
colorectal, breast and cervical cancer, such approaches
have not been applied to liver cancer [8]. The WHO
guidance for the development of national cancer pro-
grams offers some guidance for implementation [9]. The
WHO conceptualizes its model around disease progres-
sion and is focused around six dimensions: prevention,
early detection, diagnosis/treatment, pain relief/palliative
care, cancer control research, and surveillance. One of
the limitations of this approach is that it distinguishes
between appropriate strategies that should be used in
countries with low, middle and high levels of resources-
ab a r r i e rt oac o m m o np o l i c yf r a m e w o r kt h a tw o u l db e
appropriate for a pan-Asian response [10].
This paper reports the findings of a study aimed at
identifying strategies appropriate for inclusion in a com-
prehensive liver cancer control plan and at assessing the
relative priorities among these strategies. We also
sought to compare the implied priorities in the qualita-
tive data (i.e. via semi-quantification using frequency
analysis) to those found using a quantitative stated-pre-
ference methodology (conjoint analysis)-with a particu-
lar focus on Asia.
Our research is of interest to those focused on liver
cancer control, especially in Asia, for three reasons.
First, beyond clinical guidelines, there is very little in the
way of comparative research on liver cancer policy inter-
nationally. This paucity of data extends even to basic
epidemiological data on HCC, which are fragmented
and come from diverse populations, using different
methodologies and from studies performed at different
times [2]. Second, while Japan and Taiwan have demon-
strated successful strategies to combat HCC, especially
through HBV vaccination and control, there is an
absence of models of best practice for comprehensive
liver cancer control beyond HBV vaccination in most
countries of Asia [3,11,12]. Third, there are few tem-
plates available for the development of comprehensive
cancer control plans for liver cancer, and it is uncertain
if general cancer-control frameworks, such as the one
proposed by the WHO [9], are relevant for liver cancer
control.
We also make an important methodological contribu-
tion that is relevant to a wider audience of policy
makers and health services researchers. Specifically, we
demonstrate that while qualitative methods are valuable
in identifying strategies [13], semi-quantification meth-
ods such as frequency analysis [14] may be less desirable
for prioritization [15]. We demonstrate this by compar-
ing our frequency data with the results of a conjoint
analysis-a qualitative stated-preference method [16] that
is increasingly used to identify priorities for health care
policy [17-19] and more broadly in health services
research [20-22].
Methods
The study utilized both qualitative and quantitative
research methods. First, in-depth, open-ended interviews
were used to identify possible strategies and to explore
possible priorities using frequency analysis, a common
semi-quantification method [14]. Qualitative methods
are an important method for identifying complex issues
in health care, including priority setting [23,24], and are
an important way to include clinical stakeholders in
decision making processes [25-27], including the study
of cancer care and coordination [28-30]. Second, quanti-
tative stated-preference methods were used to focus
more on the priorities for Asia and to compare the
implied priorities based on the qualitative data.
All participants were informed about the study and its
potential risks and benefits. Participation in the study
was voluntary and respondents were not reimbursed for
participation. The study was deemed exempt from
human subjects consideration from the Johns Hopkins
University, Bloomberg School of Public Health Institu-
tional Review Board (IRB). All respondents were guaran-
teed anonymity and confidentially.
Identification (qualitative)
Respondents for the qualitative study were purposively
sampled to constitute a geographically and profession-
ally diverse sample of clinical experts in liver cancer and
related disease [31]. Potential respondents were actively
involved in clinical practice, academic medical centers
and/or policy relating to the prevention, detection and/
or management of liver cancer. Potential respondents
were identified through published literature, medical
societies and peer referral. Respondents were included if
they were i) working in liver disease and liver cancer in
their country; ii) involved in HCC clinical practice and
policy; iii) active members in national and international
liver associations and/or published extensively in peer
review journals, and were excluded if they were not
board certified or licensed to practice medicine in their
countries and with at least three years of clinical experi-
ence or were unwilling or unable to complete the
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all interviews.
It is clear that our focus on clinical expertise is restric-
tive, but we wanted to ground our results in those who
actually implement liver cancer control. This said, other
stakeholders, including patients, family members, nur-
sing staff or community leaders, may have given impor-
tant insights. While this certainly is a limitation in our
study, we aimed at assessing complex clinical issues, and
as such needed experts who were experienced with dis-
cussing national liver cancer policies.
Information about the study and an invitation to parti-
cipate was sent to respondents via mail or email in Eng-
lish, and in the respondents’ native language where
necessary. If no response was received within two
weeks, follow-up included a second email and/or tele-
phone call.
Open-ended qualitative interviews were conducted via
face-to-face interviews or, in a limited number of
instances, as telephone interviews. Multiple interviewers
were used so as to accommodate multiple languages,
with many of the interviews completed by the study lea-
ders (JB, BB), an important triangulation method.
After respondents were informed about the study and
consented to participate, th e yw e r ea s k e da b o u tt h e i r
country’s “strategies to promote liver cancer prevention,
treatment and research“ and then “the main gaps in
public policy.” Finally, respondents were asked “if you
had an opportunity to develop a comprehensive liver
cancer control strategy, what elements would it cover?“
Interviews were recorded, transcribed (translated
where necessary) and systematically analyzed in con-
junction with any field notes. Respondents were allowed
and encouraged to discuss other factors via open-ended
questioning, but conversations were facilitated through
the use of a comprehensive aide memoire based on pre-
vious research [10]. While saturation of themes was
achieved after 16 interviews, we completed 20 interviews
to facilitate semi-quantification.
Analysis was guided by Interpretive Phenomenological
Analysis (IPA) [32] in order to capture respondents’
experiences, perceptions, practices, and processes asso-
ciated with liver cancer control. Data were initially
reviewed and coded by two researchers, including one
who participated in data collection and one who did
not. To ensure reliability, coding was compared and dis-
cussed with senior study members (JB and BB), and a
final selection and appropriate labeling of identified
themes was determined.
Triangulation methods included the use of multiple
interviewers and analysts, geographical and professional
heterogeneity of respondents, the comparison of tran-
scripts with field notes, and comparison of results to the
published literature via a targeted literature review.
Content experts (MK, KO, K-HH and S-LY) were con-
sulted to ensure the validity of interpretation and to
resolve any ambiguity in the data. After this, the two
researchers reviewed the data to identify representative
quotes and to ensure the reliability of the coding.
Finally, to ensure that this manuscript reported all rele-
vant information, we utilized the RATS guidelines
[33,34].
Prioritization (qualitative)
The use of numeration and/or semi-quantification in
qualitative research remains controversial [35,36]. This
said, such methods are frequently used in health care
research [37-39], and are called for by the RATS guide-
lines [34]. Within the framework of IPA, numeration
through an analysis of the frequency with which a
t h e m ei ss u p p o r t e dc a nb eu s e da sa ni n d i c a t o ro fi t s
importance. As noted by Smith and colleagues [32]:
“...it makes sense to think of the frequency with which
emergent themes appear as one (though not the only)
indication of the relative importance and relevance...”
To examine the potential relative importance of the
identified strategies, we examined the frequency with
which these strategies (and any sub-ordinate concepts)
were discussed [40]. Rather than examine the frequency
within a respondent, we report the percentage of the
respondents making any reference to each of the inden-
tified themes.
Prioritization (quantitative)
As a means of offering a more quantitative assessment
of importance, we developed and implemented conjoint
analysis to examine the importance that respondents
placed on the identified strategies. While it would have
been beneficial to draw such data from the same
respondents who participated in the qualitative research,
it was decided to recruit new respondents from a single
geographic region.
Conjoint-analysis methods, and more specifically dis-
crete choice experiments, are grounded in both mathe-
matical psychology and economic theory [41,42]. They
are based on the notion of the assessment of multiple
stimuli (referred to as objects or attributes) that are
combined to create vignettes or profiles that are pre-
sented to respondents in order to evoke an action,
choice, or valuation [43]. While such methods are
widely used in health care [20-22], they have more
recently been applied to examine issues associated with
liver cancer control [44-46].
Our approach to conjoint analysis is similar to that of
Bridges et al. [19], where conjoint analysis cards are
developed to present a number of attributes (or objects)
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nario in a conjoint analysis task, the attribute is either
turned on or off [47]. Rather than identifying the best
object in each profile, we present competing plans that
represent mutually exclusive and exhaustive subsets of
the 11 attributes identified in the qualitative section.
Our experimental design utilized a 2^11 main-effects
orthogonal design from a catalogue of designs [48]. This
design consisted of a 12 × 11 matrix, with each row
representing a specific experiment and each column
representing the 11 strategies identified from the quali-
tative method. Each cell in the matrix was either a 0 or
1 and in developing the pair tasks we interpreted 0 as
implying that the strategy should be assigned to the left
plan and 1 as assigning the strategy to the plan on the
right. The properties of the design were rigorously
tested and the results cards did constitute a balanced,
orthogonal, and minimal (i.e. zero) overlap design [49].
An example of the conjoint analysis task is provided in
Figure 1, where a respondent is asked to identify which
of two national liver cancer control plans would have
the most impact in their own country.
Potential respondents for the conjoint analysis were
identified in China, Japan and South Korea by country
experts (MK, KO, KH and SY) and the inclusion/exclu-
sion criteria from our qualitative analysis were used, as
were the recruitment procedures. Again, we did not
recruit stakeholders other than clinicians, so our results
may be biased towards their viewpoint. As the aim of
this analysis was to compare the results of the frequency
a n dc o n j o i n ta n a l y s e s ,w et h o u g h tt h a ti tw a sa p p r o p r i -
ate to use a similar sample size (n = 20). While this is
small for a conjoint analysis, it is similar to mixed meth-
ods preference studies found in the literature [13], and
many commercial and legal applications of conjoint ana-
lysis methods have used similar sample sizes (especially
when the focus is on the preferences of experts). Given
this sample size, the results should not be interpreted as
being widely generalizable, but comparable in scope to
the qualitative research.
The quantitative survey instrument was administered
to the respondents through a face-to-face interview or,
where this was not possible, the survey was sent to the
respondent and administered via a telephone interview.
Respondents were guided through the questionnaire and
answered the questions in the presence of the
researcher. Respondents were asked to select the set of
strategies they thought would be most important in a
liver cancer control plan. No other answers or justifica-
tions were sought, and this process was repeated 12
times per participant. While some applications of con-
joint analysis follow each task with an open or closed
question regarding either strength of preference, ease of
task or confidence in the answer [43], we did not
include such questions so as to minimize the time bur-
den on respondents. This said, notes were taken if
respondents made any comments on the conjoint tasks.
The primary outcome in the analysis was the liver
cancer control plan selected by the participant for each
task, which was coded as a zero if the left-hand-side was
chosen and one if the plan on the right was chosen. An
identical method was used to code the placement of the
strategies on the left and right of the choice tasks. For
the purposes of comparison, we utilized both a linear
probability model (via ordinary least squares) and logis-
tic regression to estimate choice models using SAS (Ver-
sion 9.13, Cary, NC, USA), but substantive conclusions
are draw from the latter. For both estimation methods,
robust standard errors are estimated to account for
Figure 1 An example of a conjoint analysis task.
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dent [50,51]. Hypothesis testing was based on the null
that respondents’ choices were not affected by each
strategy (i.e. the importance weight is zero). The natural
alternative hypothesis was that the importance weights
were positive (given that all factors were identified as
having priorities), however, we allowed for strategies to
have a negative sign (as was found in some previous
research [52]), and utilized a two-tailed test.
To compare the implied priorities drawn from the
qualitative and quantitative analyses, the estimated rank
of the eleven strategies is presented graphically and in
the results table. Further, the prioritization is compared
between the qualitative and quantitative methods (and
among the two quantitative estimation techniques)
using the Spearman’s Rho [53].
Strengths and weaknesses
This is the first paper to focus on the development of
strategies for inclusion in a comprehensive liver cancer
control program, and in doing so we demonstrate three
important issues. First, there is a paucity of robust scien-
tific research to inform the development of evidence-
based cancer control plans. Second, preferences-based
methods, both qualitative and quantitative, are valuable
in identifying and prioritizing control strategies from the
perspective of local stakeholders. Finally, such methods
offer an important alternative to consensus methods
that can be driven by “strong personalities”, rather than
generalizable data.
There are also several weaknesses in the research
underpinning this paper. First, while it is clear that this
is subjective research, it is somewhat unclear who the
best subjects to recruit are. In some respects our
respondents are too homogeneous (i.e. clinicians with a
national or international profile), and we have omitted
many important viewpoints (other clinical experts, pol-
icy makers/leaders and patients/advocates). On the
other side, our respondents are heterogeneous, spanning
many countries that may have different priorities, which
may be biasing our results towards the null. Second,
while this method is focused on the comparison of two
methods (one qualitative, one quantitative), they have
different samples-the former being more international to
identify a range of possible strategies, the latter focusing
on only three, albeit geographically close, countries.
Finally, we have used a rather small sample size to illus-
trate conjoint analysis, and a much larger sample would
be required to ensure generalizability of our results.
Given these weaknesses, there are several limitations
in our research that must be addressed. First, while the
study was primarily focused on the identification of pos-
sible strategies, this should not be considered as an
exhaustive set. Second, while this study presents data on
priorities, the primary purpose is to demonstrate the
limitation of qualitative methods in identifying priorities
a n dt oi l l u s t r a t et h eb e n e f i to fc o n j o i n ta n a l y s i s ,n o tt o
offer a definitive prioritization of strategies for Asia.
Finally, although the data presented here are somewhat
novel, more research is needed to see how priorities
vary across countries and other stakeholders and to
identify which priorities are common in Asia, and which
are specific to individual countries in the region.
Results
Identification (qualitative)
Invitations to participate in the open-ended interviews
were sent to 25 possible respondents, all of who met the
eligibility criteria. One respondent refused to participate,
and a further four consented, but a mutually agreeable
time to schedule the interview could not be identified
before the desired number of respondents was reached.
Twenty interviews were conducted between February
and June 2010 with experts based in eleven different
countries (Australia, China, France, Germany, Italy,
Japan, Spain, South Korea, Taiwan, Turkey and United
States). The average duration of the interviews was 34
minutes (range 16-80 minutes).
Many respondents found the discussion of compre-
hensive liver cancer control a complicated task. As one
respondent put it “My gosh, that is a 40 hour discussion,
it would cover many things“, and another cautioned at
the end of a detailed discussion “Those are some points
[but] I am not being complete.” An example of the range
of problems that need to be addressed by a comprehen-
sive liver cancer control program was conveyed by one
respondent:
“We will need to start with identifying the patients
at-risk, we would then, after identifying those
patients, need to come out with a surveillance strat-
egy to monitor these patients regularly to minimize
the chance that we overlooked the development of
liver cancer in these patients, then we will need to
have a general guideline on who should treat these
patients meaning that they should be treated in spe-
cialized liver cancer centers that should be part of
comprehensive cancer centers, and then we would
need to have a study program using new drugs for
the adjuvant treatment of those patients that have
been treated and also palliative strategies to provide
the best level of care for patients with incurable liver
cancer.”
Based on these interviews, 11 possible strategies of a
comprehensive liver cancer control plan emerged as key
themes, including Access to treatments; Centers of excel-
lence; Clinical education; Measuring social burden;
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management; National guidelines; Public awareness;
Research infrastructure; Risk-assessment and referral;
and Transplantation infrastructure. Rather than focus
on the presentation of key quotes, we analyzed the data
and worked with content experts (MK, KO, KH and SY)
to elaborate a description of each of the 11 strategies
(see table 1). This ensured that the findings constituted
both a grounded and coherent interpretation of the data.
Prioritization (qualitative)
Initial prioritization was based on the frequency with
which the 11 strategies were discussed by the 20 respon-
dents (but not accounting for multiple references within
a single interview). The frequency and rank ordering of
priorities are presented in table 2. The frequency of dis-
cussion across the key themes varied between 20-85%.
The most discussed items were Risk-assessment and
referral (85%), National guidelines (80%) and Monitoring
of at-risk populations (80%) implying that they are
potential priorities. Research infrastructure (20%), Cen-
ters of excellence (25%), Measuring social burden and
Transplantation infrastructure (both 30%) were strate-
gies that were discussed with the lowest frequency,
implying a lower priority.
Prioritization (quantitative)
Invitations were sent to 42 potential respondents. Of
these 23 (55%) consented to participate and 20 were eli-
gible to participate. Field workers noted that after the
first interviews in each country, which were all super-
vised by a senior investigator (JB or BB), respondents
reported some difficulty with the choice tasks, mainly
due to a lack of familiarity with conjoint analysis meth-
ods. Based on these concerns, all field workers discussed
these difficulties, and strategies to overcome this pro-
blem were discussed. Here an example question, that
was completed and explained, was added to ensure that
all respondents were comfortable with the survey instru-
ment and that all respondents were managed in a way
that was consistent with these early interviews. This
resolved the issue, with the remaining responders
reporting no difficultly with the tasks.
Table 2 presents the importance weights (i.e. para-
meter estimates) from choice models estimated from the
conjoint analysis data using both a linear probability
model (estimated via ordinary least squares) and logistic
regression. Robust standards errors, p-values (based on
a two tailed test) and rankings of priorities are also
shown. Statistical significance (p < 0.05) was achieved
on six strategies for both methods, with both methods
in agreement on the significance on the top five factors.
Here National statistics was significant based on OLS (p
= 0.025), but not based on the logistic model (p =
0.056). Likewise, Clinical education was significant when
considering logistic estimation (p = 0.019), but not
when using OLS (p = 0.055). Both methods identified
Measuring social burden and Risk-assessment and refer-
ral as having negative importance weights, but neither
aversion reach statistical significance. Overall, there was
a very-high level of agreement between the two methods
(rho = 0.979; p < 0.0001), so substantive findings are
drawn only from the logistic estimation.
As seen in table 2 the highest priority as estimated
using the conjoint analysis was Monitoring of at-risk
populations (p < 0.001), followed by Access to treatment
(p = 0.004), Centers of excellence (p = 0.002), Multidisci-
plinary management (p = 0.004), Public awareness (p =
0.018), National guidelines (p = 0.056) and Clinical edu-
cation (p = 0.019).
Comparison of qualitative and quantitative priorities
When comparing the priorities from the conjoint analy-
sis to the frequency analysis based on the qualitative
data, there was some positive correlation (rho = 0.20),
but this relationship was not significant (p = 0.554).
When considering the priority given to individual attri-
butes (see Figure 2), similar importance (as indicated by
their rank) was given to Monitoring of at-risk popula-
tions (qual = 2/quant = 1), Public awareness (qual = 4/
quant = 5), Access to treatment (qual = 5/quant = 2),
Clinical education (qual = 6/quant = 7), Multidisciplin-
ary management (qual = 7/quant = 4), Transplantation
infrastructure (qual = 8/quant = 8), Measuring social
burden ( q u a l=8 / q u a n t=1 0 ) ,a n dResearch infrastruc-
ture (qual = 11/quant = 9). Differences in priority
between the two methods were found for Risk-assess-
ment and referral (qual = 1/quant = 11) and Centers of
excellence (qual = 10/quant = 2), and to a lesser extent
National guidelines (qual = 2/quant = 6).
Discussion
When one considers the 11 strategies for comprehensive
liver cancer control identified in this paper, we can see
that they cover factors associated with facilitating, pro-
viding and integrating care into a single system. To
facilitate the possible implementation of these strategies,
one can conceptualize them into three categories: ante-
cedents; better care; and connection. As seen in Figure
3, this can lead to a model that relates to the ABCs of
comprehensive liver cancer control. Here Antecedents
include Clinical education, Measuring social burden and
Public Awareness, all factors that can motivate the adop-
tion of comprehensive liver cancer control. Access to
treatments, Monitoring of at-risk populations, Risk-
assessment and referral and Transplantation infrastruc-
ture are all factors aimed at providing Better care, a vital
component of any comprehensive cancer control plan.
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Strategy Description Relevant quotes
Access to
treatments
Appropriate coverage and reimbursement for necessary prevention,
surveillance, treatment, pain relief and palliative services.
“Creating access to treatment-screening is a
waste of effort if you don’t link it to care”
“The national insurance system does not fully
cover payment”
“Patients ask for new treatments, however, they
are not covered by insurance”
“It is important to eradicate drug lag and make
good medication available as soon as possible”
Centers of
excellence
Specialized liver cancer centers to provide coordinated surveillance, treatment
and research within a national liver cancer program.
“Transfer patients with a HCC diagnosis to a
tertiary hospital to receive state-of-the-art
treatment”
“There is no organization that brings all liver
cancer research together under one roof”
“Build a large center, experienced with
international techniques, with a large number
of patients”
“We need to continue to preach to establish
centers of excellence with multidisciplinary
efforts”
Clinical education Improve primary care provider’s awareness of the benefits of screening and
early treatment, and necessary skills in risk assessment.
“Most of the educational resources need to go
into educating healthcare professionals”
“Increase awareness among general practitioner,
most are not aware”
“Education of general practitioners concerning
the screening of HCC, and gastroenterologists
too”
“We need to focus on the general education for
primary care physicians so they will become
vigilant”
Measuring social
burden
Accurate measures of risk factors, cirrhosis, liver cancer, the societal costs of
illness and the benefits of improving liver cancer care.
“Research the epidemiology of liver cancer, I
think that we underestimate liver cancer by
50%”
“Prevalence, surveillance, burden of disease,
effective and cost-effective strategies”
“Know the epidemiological trend for non-
alcohol fatty liver disease and its impact on
HCC incidence”
“We need to have some comparison about how
many lives we can save if we improve”
Monitoring of at-
risk populations
National surveillance programs for at-risk patients through expert services to
diagnose HCC in early stages and improve outcomes.
“Get at-risk patients into adequate screening
programs at appropriate intervals and tested by
experts”
“Of cause surveillance programs are important
to prevent or to detect early HCC”
“There should be a national surveillance
program for liver cirrhosis”
“Monitor high-risk patients so if they develop
HCC they can be diagnosed at an early stage
and treated”
Multidisciplinary
management
Diagnosis, treatment decisions and follow-up of all HCC patients through
collaborative teams of all relevant specialists.
“Follow-up of HCC patients should be in a
multidisciplinary team of different specialists”
“Collaboration among physicians, surgeons,
radiologists and oncologists is very poor”
“Create an appropriate interdisciplinary board
where every single patient is evaluated by this
team”
“It is very important to appreciate that this
disease is heterogeneous with regards to the
etiology”
National guidelines National standards for diagnosis and guidelines for screening, surveillance,
treatment and palliation related to liver cancer.
“There are no national guidelines on how to
deal with patients with liver cancer”
“There should be a national treatment strategy
recognized and outcomes captured”
“There is a lack of standardization of clinical
diagnosis and treatment”
“Information exchange among world leaders to
prepare a global standard for prevention and
treatment”
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nents well connected. In our model, Centers of excel-
lence, Multidisciplinary management, National
guidelines and Research infrastructure are important
Connections of a comprehensive liver cancer control
plan.
The strategies identified here parallel some of the stra-
tegies embedded in the WHO guidelines for general
comprehensive cancer control with two exceptions [9].
First, strategies for pain relief/palliative care were not
identified as an important cancer control strategy by our
clinical respondents. This may have been different if
more variety in the types of stakeholders were included
in our sample (e.g. we had no nurses, patients or advo-
cates), but there may be a lack of advocacy for liver can-
cer more generally [54]. This said, pain relief/palliative
care can be seen as belonging to our Access to treatment
strategy. Second, we do not differentiate strategies for
implementation in low, middle and high income coun-
tries [10], nor did we examine such heterogeneity in
priorities. These two differences highlight the need for
further research to differentiate priorities across differ-
ent stakeholders (including advocates, where they may
exist) and across different countries in Asia and beyond.
While this paper identified certain priorities for imple-
mentation in an Asian comprehensive liver cancer con-
trol plan, it is important to compare these to current
policies in Asia. Highest priority was given to Monitor-
ing of at-risk populations, which has been shown to
facilitate early diagnosis [55]. Such surveillance pro-
grams are related to surveillance in primary care [56],
which may account for the low value given to Risk-
Table 1 Strategies for comprehensive liver cancer control (Continued)
Public awareness Programs to improve public/political awareness about risk factors, surveillance,
and survival benefits, and organized patient advocacy.
“Greater public awareness of liver disease, risk
factors and the fact that good treatments are
available”
“There is an absolute ignorance among the
public and there is a clear need for education”
“Patient groups are limited to popular types of
cancer, but HCC is mainly the cancer of the
poor”
“Support experts to handle the details of patient
advocacy so prevention and treatment could
benefit”
Research
infrastructure
Funding, personnel, and facilities to conduct relevant basic, clinical and
translational liver cancer research throughout the health system.
“There is no specific program for HCC with
public funding ... research infrastructure is
always needed”
“Train physicians who can lead clinical trials ...
we also need research nurses”
“Get thorough scientific research for HCC,
genetics, biology, the pathways, it is very
important”
“There is an uneven distribution of research
funding and the lack of grass-roots research
funding”
Risk-assessment
and referral
Risk stratification conducted by primary care providers who refer patients to
appropriate surveillance provided regularly by experts.
“Identify at-risk patients, encourage them to be
screened, and link them to appropriate care”
“Primary doctors should not be treating viral
hepatitis, they should be detecting it”
“GPs don’t consider it necessary and don’t
perform screening in patients with diagnosed
cirrhosis”
“We have very inefficient tools for identifying the
high risk patients”
Transplantation
infrastructure
Improve awareness and capacity for organ donation, more capacity for
transplantation, and alternatives to cadaveric transplantation
“The situation cannot be altered without
donors, but there is not much social
infrastructure to support it”
“It has been a major necessity to promote more
cadaveric liver transplantation for more than
decade”
“The only shortcoming is transplantation,
cadaveric transplantation is standard in other
countries”
“Real awareness of organ donation. There are
some examples in the media, but still nothing
happens”.
Representative quotes remain unidentified to ensure anonymity and confidentiality of respondents
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mer more beneficial to the latter). This said, risk stratifi-
cation may be important to target surveillance strategies
[57]. While Centers of excellence were only discussed by
a minority of respondents in the qualitative interviews,
this strategy was considered a priority in the conjoint
analysis. Such specialized centers have been shown to be
of value in early surveillance and improved outcomes
for HCC in Japan [58].
Priority was also placed on Access to treatment by
respondents in both the qualitative and quantitative por-
tions of this study. While lack of robust financing sys-
tems is a major barrier in many Asian countries,
barriers to access persist in those countries with
national health insurance. Other barriers include a lack
of reimbursement, high copayments, a lack of specialty
centers, the availability of specialists and awareness of
the disease among primary care physicians and the gen-
eral public [59]. A shortage of organ donors and subse-
quent waiting lists also pose barriers to access to
transplantation [60].
There are some omissions from our set of strategies.
For example, in addition to the absence of pain manage-
ment and palliative care, our study did not specifically
characterize hepatitis control as a strategy. However,
prevention (e.g. through HBV vaccination), treatment
and control (which would include treatment of hepatitis
associated with HCC) are within the descriptors for
Access to treatment. While quality hepatitis control
exists in many Asian countries [61,62], hepatitis control
m u s tb eap r i o r i t yi nm a n yc o u n t r i e sn o ti n c l u d e di n
this study [63,64].
Table 2 Importance of strategies for liver cancer control
Qualitative Quantitative
Strategy Frequency
(Rank)
OLS
(SE)
P-
Value
(Rank)
Logit
(SE)
P-
Value
(Rank)
Access to treatments 70% 0.192 0.010 1.146 0.004
(5) (0.07) (3) 0.40 (2)
Centers of excellence 25% 0.192 0.001 1.079 0.002
(10) (0.05) (2) 0.35 (3)
Clinical education 65% 0.108 0.055 0.625 0.019
(6) (0.05) (8) 0.27 (7)
Measuring social burden 30% -0.025 0.698 -0.185 0.613
(8) (0.06) (11) 0.37 (10)
Monitoring of at-risk
populations
80% 0.275 < .001 1.508 <
0.001
(2) (0.06) (1) 0.41 (1)
Multidisciplinary
management
35% 0.158 0.004 0.919 0.004
(7) (0.05) (4) 0.32 (4)
National guidelines 80% 0.158 0.025 0.678 0.056
(2) (0.06) (6) 0.36 (6)
Public awareness 75% 0.158 0.007 0.841 0.018
(4) (0.05) (5) 0.36 (5)
Research infrastructure 20% 0.058 0.243 0.337 0.178
(11) (0.05) (9) 0.25 (9)
Risk-assessment and
referral
85% -0.008 0.870 -0.135 0.645
(1) (0.05) (10) 0.29 (11)
Transplantation
infrastructure
30% 0.125 0.196 0.352 0.543
(8) (0.09) (7) 0.58 (8)
Robust standard errors in parentheses.
Figure 2 A comparison of priorities using qualitative and quantitative methods.
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pretations of the data in this study. One interpretation
is that valuation of some strategies in the qualitative
analysis may be as a result of framing effects in the pre-
sentation of the choice tasks. For example, Measuring
social burden, which received a negative value, was
described as “Measuring the social burden of liver can-
cer” (see Figure 1). Here respondents may have found
this label ambiguous, or as implying factors that were
not implicit in the qualitative analysis. This label may
have been better described with terms such as measur-
ing incidence or prevalence, terms that are more famil-
iar to the respondents.
Risk-assessment and referral received a negative valua-
tion despite being the most frequently discussed strategy
in the qualitative analysis. Here several factors may have
contributed to this aversion. First, the factor was
described in the conjoint tasks as “Improved risk-assess-
ment and referral by primary care” (see Figure 1), and
the “improved” m a yh a v eu n d u l yf r a m e dt h ef a c t o r
(especially for countries that have good risk-assessment
mechanisms) or made the factor ambiguous (especially
for those who do not have such mechanisms). Second, it
may have been more accurate to refer to this as “contin-
uous surveillance” of at risk populations. Third, there
was some confusion between “risk-assessment and refer-
ral"-mechanisms to stratify those at-risk of developing
HCC and referring them to appropriate care-and “moni-
toring of at-risk populations"-mechanisms of surveil-
lance for patients identified as being at-risk, preferably
in specialty care. Finally, there may be heterogeneity in
the valuation of this factor across the study countries, i.
e. this may be a priority in some countries, but not in
others, potentially because such services are already pro-
vided or because systems are not based upon primary
care providers originating risk assessment and diagnosis.
While this study is motivated by a need for compre-
hensive liver cancer control in Asia [10], it also high-
lights a more general need for more quantitative
research methods to guide priority setting in health
care. The prioritization of limited resources across com-
peting demands presents an “economic challenge and a
political puzzle” [65], but is a vital element of systematic
planning in public health [66]. While some health care
planners utilize multiple evidence sources (both qualita-
tive and quantitative) for the purposes of priority setting
[67], stakeholder engagement in policy often is limited
to nominal groups or consensus-based approaches (e.g.
Delphi techniques) [68,69]. As such, this study makes a
significant contribution towards demonstrating the value
of conjoint analysis in prioritization of health care policy
strategies and challenges the soundness of consensus-
based approaches.
Conclusions
Identified strategies can be conceptualized as the ABCs
of comprehensive liver cancer control as they focus on
Antecedents, Better care and Connections within a
national strategy. Some concordance was found between
the qualitative and quantitative methods (e.g. Monitoring
of at-risk populations), but substantial differences were
also identified (e.g. qualitative methods gave highest
priority to risk-assessment and referral, but it was the
lowest for the quantitative methods), which may be
attributed to differences between the methods and study
populations, and potential framing effects in choice
tasks. Continued research will provide more generaliz-
able estimates of priorities and account for variation
across stakeholders and countries.
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